FDA grants approval for two novel ultrasound systems from Esaote in MyLab series

Esaote's MyLab A50 and MyLab A70 Ultrasound Systems Receive FDA Clearance

Esaote, a leading manufacturer in the field of medical imaging, has received U.S. Food and Drug Administration (FDA) clearance to market its MyLab A50 and MyLab A70 ultrasound systems. These advanced systems are designed to cater to a wide range of clinical environments and support both routine diagnostics and advanced imaging.

The MyLab A50 and A70 ultrasound systems were previously unveiled and have since been presented to the international medical community. Esaote showcased the systems' flexibility across various clinical environments, emphasising their user-friendly design and compact layout.

The systems are equipped with a conventional and touch control interface, making them easy to operate for healthcare professionals. In addition, the MyLab A50 and A70 ultrasound systems feature strain analysis, a technology that enables detailed and multiparametric assessments.

The MyLab A50 and A70 ultrasound systems are also designed to support cardiac ultrasound imaging using strain analysis. Advanced imaging options for the systems include liver elastography and attenuation imaging.

The user-friendly interface of the MyLab A50 and A70 ultrasound systems is another key feature, ensuring that they can be easily integrated into various clinical workflows. The systems are intended for use by the international medical community, providing them with a versatile tool for diagnostic imaging.

With the FDA clearance, Esaote's MyLab A50 and MyLab A70 ultrasound systems are now available for purchase in the United States. The systems' combination of advanced technology, user-friendly design, and flexibility make them a valuable addition to any clinical environment.